ArticleiScience2026
Pathway potency in methylation altered network reveals lung cancer branching evolution and hallmarks.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pattools‑implemented methylation vector analysis reveals aberrant subtype‑specific methylation in lung cancer across tissue and plasma cfDNA.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inability to profile the dynamic evolution and heterogeneity of cancer cells presents a significant barrier to effective early screening for lung cancer. By mapping pathway interactions within and beyond gene systems, one can decode their synergistic interactions underlying molecular stability and state transitions. To this end, we propose an efficient approach that derives pathway potency characterization from methylation altered sample specific networks. Applying it to lung adenocarcinoma samples uncovers a seven-state trajectory across three branching points. We show that while patient survival tends to decline within each state, it improves when the cancer transitions to a new state at branching points, which offers a more dynamic view of progression. Our approach also identifies the top feature pathways that distinguish different cancer states. Given the marked heterogeneity in pathway interplay patterns, we propose this method holds promise for decoding cancer complexity and eventually resolving critical issues in early screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.